Compare SWBI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | ARVN |
|---|---|---|
| Founded | 1852 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.3M | 658.2M |
| IPO Year | 2000 | 2018 |
| Metric | SWBI | ARVN |
|---|---|---|
| Price | $15.21 | $8.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | $14.00 | ★ $15.05 |
| AVG Volume (30 Days) | 386.4K | ★ 854.3K |
| Earning Date | 06-17-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $262,600,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $309.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $6.06 |
| 52 Week High | $15.79 | $14.22 |
| Indicator | SWBI | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 35.45 |
| Support Level | $13.90 | $7.35 |
| Resistance Level | $15.24 | $10.18 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 68.48 | 23.34 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.